

# Giuseppe Palermo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4244566/publications.pdf>

Version: 2024-02-01

28  
papers

436  
citations

840119

11  
h-index

752256

20  
g-index

33  
all docs

33  
docs citations

33  
times ranked

644  
citing authors

#	ARTICLE	IF	CITATIONS
1	Imaging in Prostate Cancer Staging: Present Role and Future Perspectives. <i>Urologia Internationalis</i> , 2012, 88, 125-136.	0.6	54
2	ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk BCG failure non muscle invasive bladder cancer: 3 years follow-up outcomes. <i>BMC Cancer</i> , 2018, 18, 1224.	1.1	51
3	The new surgical robotic platform HUGO <sup>TM</sup> RAS: System description and docking settings for robot-assisted radical prostatectomy. <i>Urologia</i> , 2022, 89, 603-609.	0.3	35
4	Male sexual dysfunction in patients with chronic end-stage renal insufficiency and in renal transplant recipients. <i>Archivio Italiano Di Urologia Andrologia</i> , 2016, 87, 299.	0.4	34
5	Sexual outcomes after organ potency-sparing surgery and glans reconstruction in patients with penile carcinoma. <i>Indian Journal of Urology</i> , 2013, 29, 119.	0.2	31
6	Imaging in Bladder Cancer: Present Role and Future Perspectives. <i>Urologia Internationalis</i> , 2010, 85, 373-380.	0.6	26
7	Artificial urinary sphincter significantly better than fixed sling for moderate post-prostatectomy stress urinary incontinence: a propensity score matched study. <i>BJU International</i> , 2021, 127, 229-237.	1.3	23
8	Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 315-324.	0.7	18
9	Implementation of frailty preoperative assessment to predict outcome in patients undergoing urological surgery: a systematic review and meta-analysis. <i>BJU International</i> , 2021, 127, 507-517.	1.3	17
10	Titanized Transobturator Sling Placement for Male Stress Urinary Incontinence Using an Inside-out Single-incision Technique: Minimum 12-Months Follow-up Study. <i>Urology</i> , 2018, 115, 144-150.	0.5	15
11	Postoperative Quality of Life in Patients with Ileal Neobladder at Short-, Intermediate- and Long-Term Follow-Up. <i>Urologia Internationalis</i> , 2016, 97, 54-60.	0.6	14
12	Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2019, 2, 576-583.	2.6	14
13	The challenges of Bacillus of Calmette-Guerin (BCG) therapy for high risk non muscle invasive bladder cancer treatment in older patients. <i>Journal of Geriatric Oncology</i> , 2018, 9, 507-512.	0.5	11
14	Role of SOCS3 Evaluated by Immunohistochemical Analysis in a Cohort of Patients Affected by Prostate Cancer: Preliminary Results. <i>Urologia</i> , 2012, 79, 4-8.	0.3	10
15	High-intensity focused ultrasound in prostate cancer: Today's outcomes and tomorrow's perspectives. <i>Scandinavian Journal of Urology</i> , 2013, 47, 179-187.	0.6	10
16	Improved Non-Invasive Diagnosis of Bladder Cancer with an Electronic Nose: A Large Pilot Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4984.	1.0	9
17	Clinical, Pathological and Molecular Prognostic Factors in Prostate Cancer Decision-Making Process. <i>Urologia</i> , 2016, 83, 14-20.	0.3	8
18	Objectively improving appropriateness of absorbent products provision to patients with urinary incontinence: The DIAPPER study. <i>Neurourology and Urodynamics</i> , 2018, 37, 485-495.	0.8	6

#	ARTICLE	IF	CITATIONS
19	Second-Line Conservative Device-Assisted Intravesical Treatment in Selected Patients With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e100-e119.	0.9	6
20	The Role of Bladder Epicheck Test In Follow-Up of Patients with Non-Muscle Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e271-e275.	0.9	6
21	Multiparametric magnetic resonance imaging of the prostate: Lights and shadows. <i>Urologia</i> , 2021, 88, 280-286.	0.3	5
22	Local relapse of prostate cancer after primary definitive treatment: the management. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2016, 68, 282-92.	3.9	5
23	Microbiological follow-up of Nosocomial Infections in a Single Urological Center. <i>Urologia</i> , 2012, 79, 147-151.	0.3	3
24	Rate of clinically significant prostate cancer on repeat saturation biopsy after a diagnosis of atypical small acinar proliferation. <i>Urologia</i> , 2021, 88, 194-199.	0.3	3
25	High intensity focused ultrasound as first line salvage therapy in prostate cancer local relapse after radical prostatectomy: 4-year follow-up outcomes. <i>Minerva Urology and Nephrology</i> , 2016, 69, 93-100.	1.3	2
26	MP83-01 ELECTROMOTIVE DRUG ADMINISTRATION (EMDA) OF MITOMYCIN C AS FIRST LINE SALVAGE THERAPY IN HIGH RISK BCG-FAILURE NON MUSCLE INVASIVE BLADDER CANCER: 3-YEARS FOLLOWUP OUTCOMES. <i>Journal of Urology</i> , 2018, 199, .	0.2	1
27	Urinary bladder leiomyosarcoma with osteoclast-like multinucleated giant cells: a case report. <i>BMC Cancer</i> , 2019, 19, 763.	1.1	1
28	The Occult Urothelial Cancer. <i>Urologia</i> , 2016, 83, 55-60.	0.3	0